TABLE 2.

Feasibility and tolerability of study protocol

Variable	All patients (n = 30)
Completed all therapy, n (%)	22 (73)
Dose reduction, n (%)
Single dose reduction, any drug	15 (50)
At least 1 gemcitabine dose reduction	14 (47)
At least 1 cisplatin dose reduction	6 (20)
At least 1 nab-paclitaxel dose reduction	14 (47)
2+ dose reductions, any drug	5 (17)
2+ gemcitabine dose reductions	2 (7)
2+ cisplatin dose reductions	0 (0)
2+ nab-paclitaxel dose reductions	3 (10)
Any grade ≥ 3 AEs, n (%)	10 (33)
Grade ≥ 3 hematologic AEs, n (%)
Anemia	1 (3)
Febrile neutropenia	1 (3)
Leukocytosis	1 (3)
Leukopenia	1 (3)
Neutropenia	5 (17)
Elevated ALT	1 (3)
Grade ≥ 3 gastrointestinal AEs, n (%)
Diarrhea	2 (7)
Treatment-related mortality, n (%)	0 (0)

AE adverse event